奇洛斯塔与克洛皮多格雷尔在急性大血管中度和中度至重度缺血性中风:一个随机对照试验
Sherihan Rezk Ahmed1, Mohamed Fouad Elsayed Khalil2, Mohamed Ismaiel3
1Neurology Department, Faculty of Medicine, Kafr El-Sheikh University, Kafr El-Sheikh, Egypt.
概括
与克洛皮多格雷尔相比,基洛斯塔显著降低了急性大血管封闭 (LVO) 缺血性中风患者的复发性中风率和出血并发症. 这项研究是北非首次评估中度至重度LVO中风的这些治疗方法.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 临床试验 临床试验
背景情况:
- 大血管封闭 (LVO) 占有超过三分之一的缺血性中风.
- 以前对西洛斯塔与克洛皮多格雷尔用于中风管理的试验主要在亚洲进行,重点是轻微的中风或短暂性缺血性发作 (TIA).
- 这项研究是对西洛斯塔与克洛皮多格雷尔在北非中度至重度缺血性中风的急性LVO的首次评估.
研究的目的:
- 评估西洛斯塔与克洛皮多格雷尔相比的疗效和安全性,用于首次发生大血管封闭 (LVO) 缺血性中风的患者.
- 评估中度和中度至重度缺血性中风患者的结局.
主要方法:
- 一项随机试验,涉及580名中度至重度LVO缺血性中风的参与者.
- 参与者接受了西洛斯塔或克洛皮多格雷尔,包括加载剂和维持剂.
- 对被录取的患者进行了治疗意向分析.
主要成果:
- 与克洛皮多格雷尔组 (14.8%) 相比,西洛斯塔组 (10.0%) 的新中风发生率明显较低 (HR 0.37;P=0.03).
- 与药物相关的出血并发症在西洛斯塔 (2.8%) 与克洛皮多格雷尔 (5.9%) 相比较少 (HR 0.29;P=0.008).
- 两组之间没有观察到因血管事件造成的3个月死亡率或不良的修改兰金度表 (mRS) 评分的显著差异.
结论:
- 在急性LVO中度至重度缺血性中风患者中,在中风发作后24小时内给药西洛斯塔导致更好的临床结果,由较低的复发性中风率证明.
- 与克洛皮多格雷尔相比,西洛斯塔在脑梗塞的出血转化和药物诱导的外周出血副作用方面表现出更高的安全性.
- 虽然西洛斯塔在中风复发和出血方面显示出好处,但与血管死亡和功能障碍有关的结果在三个月后在两种治疗方法之间没有显著差异.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
396
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
396
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
108
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
108
01:29Inflammatory Bowel Disease IV: Pharmacological Management
80
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
80
01:29Drugs for Treatment of Ulcerative Colitis in IBD
106
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
106
01:21Drugs for Treatment of Constipation-Predominant IBS
111
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
111
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
87
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
87